Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival

BACKGROUND: Immune checkpoint inhibitors (ICIs) are increasingly used to treat advanced malignancies. However, they are associated with the development of multiple gastrointestinal immune-related adverse events (GI-irAEs). We aimed to evaluate the types and severity of GI-irAEs associated with ICI t...

Descripción completa

Detalles Bibliográficos
Autores principales: Alomari, Mohammad, Al Ashi, Suleiman, Chadalavada, Pravallika, Khazaaleh, Shrouq, Covut, Fahrettin, Al Momani, Laith, Elkafrawy, Ahmed, Padbidri, Vinay, Funchain, Pauline, Campbell, Donald, Romero-Marrero, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076156/
https://www.ncbi.nlm.nih.gov/pubmed/35572476
http://dx.doi.org/10.14740/gr1491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076156/
https://www.ncbi.nlm.nih.gov/pubmed/35572476
http://dx.doi.org/10.14740/gr1491

Ejemplares similares